Extensior 0.5mg 1.5ml Prefilled Pen
Rs. 4,999.00
Title
Extensior 0.5mg 1.5ml Prefilled Pen
Prescription drug
About
Extensior 0.5mg Prefilled Pen is a prescription injectable medicine containing Semaglutide 0.5mg, a GLP-1 receptor agonist. It is a once-weekly subcutaneous injection used after the initial 0.25mg dose period, to further improve blood sugar control in type 2 diabetes and support long-term weight management. Each 1.5ml pen contains 4 weekly doses providing one month of treatment at the maintenance dose level.
Usage Instructions
Inject once weekly subcutaneously in the abdomen, thigh, or upper arm. Use on the same day each week. Rotate injection sites. This dose is typically prescribed after 4 weeks on the 0.25mg starting dose. Follow your doctor's instructions for dose escalation. Do not double the dose if a weekly injection is missed.
Benefits
Provides stronger blood sugar (glycaemic) control compared to the starting 0.25mg dose
Supports sustained weight loss in patients with obesity or overweight
Reduces the risk of major cardiovascular events in high-risk adults
Convenient once-weekly prefilled pen with 4 doses per unit
Reduces HbA1c levels significantly when used alongside diet and exercise
How It Works
At the 0.5mg dose, semaglutide continues to act as a GLP-1 receptor agonist — stimulating glucose-dependent insulin release, suppressing excess glucagon, slowing gastric emptying, and reducing appetite through central nervous system activity. The higher dose provides enhanced and more sustained glucoregulatory effects compared to the initiation dose.
Side Effects
Common side effects include nausea, vomiting, diarrhoea, stomach pain, constipation, headache, dizziness, and fatigue. These often improve after the first few weeks. Serious risks include pancreatitis, gallbladder problems, kidney impairment, diabetic retinopathy complications, and severe allergic reactions.
Safety Advice
Do not use if personal or family history of medullary thyroid cancer or MEN 2 syndrome.
Not for type 1 diabetes or diabetic ketoacidosis.
Stop at least 2 months before planned pregnancy; not safe during pregnancy or breastfeeding.
Not approved for children under 12 years.
Monitor renal function in patients with kidney disease during treatment.
Refrigerate before first use.
Storage
Store unused pens at 2°C–8°C in a refrigerator. Do not freeze. After first use, store below 30°C or refrigerated for up to 56 days. Protect from sunlight and heat.
Extensior 0.5mg Prefilled Pen is a prescription injectable medicine containing Semaglutide 0.5mg, a GLP-1 receptor agonist. It is a once-weekly subcutaneous injection used after the initial 0.25mg dose period, to further improve blood sugar control in type 2 diabetes and support long-term weight management. Each 1.5ml pen contains 4 weekly doses providing one month of treatment at the maintenance dose level.
Usage Instructions
Inject once weekly subcutaneously in the abdomen, thigh, or upper arm. Use on the same day each week. Rotate injection sites. This dose is typically prescribed after 4 weeks on the 0.25mg starting dose. Follow your doctor's instructions for dose escalation. Do not double the dose if a weekly injection is missed.
Benefits
Provides stronger blood sugar (glycaemic) control compared to the starting 0.25mg dose
Supports sustained weight loss in patients with obesity or overweight
Reduces the risk of major cardiovascular events in high-risk adults
Convenient once-weekly prefilled pen with 4 doses per unit
Reduces HbA1c levels significantly when used alongside diet and exercise
How It Works
At the 0.5mg dose, semaglutide continues to act as a GLP-1 receptor agonist — stimulating glucose-dependent insulin release, suppressing excess glucagon, slowing gastric emptying, and reducing appetite through central nervous system activity. The higher dose provides enhanced and more sustained glucoregulatory effects compared to the initiation dose.
Side Effects
Common side effects include nausea, vomiting, diarrhoea, stomach pain, constipation, headache, dizziness, and fatigue. These often improve after the first few weeks. Serious risks include pancreatitis, gallbladder problems, kidney impairment, diabetic retinopathy complications, and severe allergic reactions.
Safety Advice
Do not use if personal or family history of medullary thyroid cancer or MEN 2 syndrome.
Not for type 1 diabetes or diabetic ketoacidosis.
Stop at least 2 months before planned pregnancy; not safe during pregnancy or breastfeeding.
Not approved for children under 12 years.
Monitor renal function in patients with kidney disease during treatment.
Refrigerate before first use.
Storage
Store unused pens at 2°C–8°C in a refrigerator. Do not freeze. After first use, store below 30°C or refrigerated for up to 56 days. Protect from sunlight and heat.
₹4,999.00
Inclusive of all taxes
Quantity
Fresh Stock
Guaranteed
Guaranteed
Secure & Hygienic
Packaging
Packaging
Verified & Trusted
Supplements
Supplements
Secure
Payment
Payment
About
Extensior 0.5mg Prefilled Pen is a prescription injectable medicine containing Semaglutide 0.5mg, a GLP-1 receptor agonist. It is a once-weekly subcutaneous injection used after the initial 0.25mg dose period, to further improve blood sugar control in type 2 diabetes and support long-term weight management. Each 1.5ml pen contains 4 weekly doses providing one month of treatment at the maintenance dose level.
Usage Instructions
Inject once weekly subcutaneously in the abdomen, thigh, or upper arm. Use on the same day each week. Rotate injection sites. This dose is typically prescribed after 4 weeks on the 0.25mg starting dose. Follow your doctor's instructions for dose escalation. Do not double the dose if a weekly injection is missed.
Benefits
Provides stronger blood sugar (glycaemic) control compared to the starting 0.25mg dose
Supports sustained weight loss in patients with obesity or overweight
Reduces the risk of major cardiovascular events in high-risk adults
Convenient once-weekly prefilled pen with 4 doses per unit
Reduces HbA1c levels significantly when used alongside diet and exercise
How It Works
At the 0.5mg dose, semaglutide continues to act as a GLP-1 receptor agonist — stimulating glucose-dependent insulin release, suppressing excess glucagon, slowing gastric emptying, and reducing appetite through central nervous system activity. The higher dose provides enhanced and more sustained glucoregulatory effects compared to the initiation dose.
Side Effects
Common side effects include nausea, vomiting, diarrhoea, stomach pain, constipation, headache, dizziness, and fatigue. These often improve after the first few weeks. Serious risks include pancreatitis, gallbladder problems, kidney impairment, diabetic retinopathy complications, and severe allergic reactions.
Safety Advice
Do not use if personal or family history of medullary thyroid cancer or MEN 2 syndrome.
Not for type 1 diabetes or diabetic ketoacidosis.
Stop at least 2 months before planned pregnancy; not safe during pregnancy or breastfeeding.
Not approved for children under 12 years.
Monitor renal function in patients with kidney disease during treatment.
Refrigerate before first use.
Storage
Store unused pens at 2°C–8°C in a refrigerator. Do not freeze. After first use, store below 30°C or refrigerated for up to 56 days. Protect from sunlight and heat.
Extensior 0.5mg Prefilled Pen is a prescription injectable medicine containing Semaglutide 0.5mg, a GLP-1 receptor agonist. It is a once-weekly subcutaneous injection used after the initial 0.25mg dose period, to further improve blood sugar control in type 2 diabetes and support long-term weight management. Each 1.5ml pen contains 4 weekly doses providing one month of treatment at the maintenance dose level.
Usage Instructions
Inject once weekly subcutaneously in the abdomen, thigh, or upper arm. Use on the same day each week. Rotate injection sites. This dose is typically prescribed after 4 weeks on the 0.25mg starting dose. Follow your doctor's instructions for dose escalation. Do not double the dose if a weekly injection is missed.
Benefits
Provides stronger blood sugar (glycaemic) control compared to the starting 0.25mg dose
Supports sustained weight loss in patients with obesity or overweight
Reduces the risk of major cardiovascular events in high-risk adults
Convenient once-weekly prefilled pen with 4 doses per unit
Reduces HbA1c levels significantly when used alongside diet and exercise
How It Works
At the 0.5mg dose, semaglutide continues to act as a GLP-1 receptor agonist — stimulating glucose-dependent insulin release, suppressing excess glucagon, slowing gastric emptying, and reducing appetite through central nervous system activity. The higher dose provides enhanced and more sustained glucoregulatory effects compared to the initiation dose.
Side Effects
Common side effects include nausea, vomiting, diarrhoea, stomach pain, constipation, headache, dizziness, and fatigue. These often improve after the first few weeks. Serious risks include pancreatitis, gallbladder problems, kidney impairment, diabetic retinopathy complications, and severe allergic reactions.
Safety Advice
Do not use if personal or family history of medullary thyroid cancer or MEN 2 syndrome.
Not for type 1 diabetes or diabetic ketoacidosis.
Stop at least 2 months before planned pregnancy; not safe during pregnancy or breastfeeding.
Not approved for children under 12 years.
Monitor renal function in patients with kidney disease during treatment.
Refrigerate before first use.
Storage
Store unused pens at 2°C–8°C in a refrigerator. Do not freeze. After first use, store below 30°C or refrigerated for up to 56 days. Protect from sunlight and heat.